The Treatment of Acute Rheumatic Fever
Nigel Wilson, Anthony Concannon, JOHN ERSKINE MALCOLM, Sarka Davidakova, W. J. Martin, Rachel Webb, Nicole J. Moreland
Abstract
Hydroxychloroquine (HCQ) suppresses an interleukin-1β-granulocyte-macrophage colony-stimulating factor cytokine axis, reported to be dysregulated in peripheral blood mononuclear cells of acute rheumatic fever patients ex vivo. We describe HCQ treatment for 2 patients with rheumatic carditis and a protracted inflammatory course. HCQ was associated with control of inflammatory markers, control of pericarditis in first patient and stabilization of progressive carditis in the second patient.
Topics & Concepts
MedicineHydroxychloroquineCarditisPericarditisImmunologyAcute rheumatic feverRheumatic feverInternal medicineDiseaseInfectious disease (medical specialty)Coronavirus disease 2019 (COVID-19)Streptococcal Infections and TreatmentsHematological disorders and diagnosticsInflammasome and immune disorders